Pfizer-BioNTech hopes to get approval to use the vaccine for children aged 5 to 11 years.
Health Canada’s chief medical adviser has highlighted that Pfizer-BioNTech’s COVID-19 vaccine for children between the ages of 5 to 11 after review there might be positive feedback for a vaccine to be in use.
Dr. Supriya Sharma told a Public Health Agency of Canada briefing in Ottawa today that with the rise in Covid-19 it is on a priority basis and the team is reviewing data and that data is not just the clinical data, but as well the formulation which will decide the Canadian context for the possible use in children.
Pfizer-BioNTech became the first company to seek Heath’s Canada’s approval for a pediatric COVID-19 vaccine which was declared three weeks ago. Other vaccine organizations such as Moderna, are working on children’s formulations.
While talking about children aged 12 and older are already approved for the adult formulation, the pediatric formulation would be given in two smaller doses — 10 mcg (micrograms), instead of the 30 mcg used for those over the age of 12.
While Sharma last month confirmed that children’s version of the vaccine is “slightly different” from the adult one, it contains the same mRNA and works the same way.
Vaccine from Novavaz has complete submission the review of that product will continue which was commented by the chief medical adviser.
Dr. Theresa Tam the Chief Public Health Officer said that for the second week in a row, under 12 children will continue to have the highest incidence rates across all age groups.
While elaborating on the rate of vaccines for kids aged 12 to 17 Tam said though the children group got their shots later than adults still the data shows a good response in uptake at the beginning of the vaccination campaign.